Literature DB >> 20647995

Rheumatoid cachexia and cardiovascular disease.

Gregory D Summers1, Giorgos S Metsios, Antonios Stavropoulos-Kalinoglou, George D Kitas.   

Abstract

Both cachexia and cardiovascular disease are strongly associated with rheumatoid arthritis (RA) and linked to the chronic inflammatory process. Typically, rheumatoid cachexia occurs in individuals with normal or increased BMI (reduced muscle mass and increased fat mass). Classic cachexia (reduced muscle mass and reduced fat mass) is rare in RA but is associated with high inflammatory activity and aggressive joint destruction in patients with a poor cardiovascular prognosis. Conversely, obesity is linked to hypertension and dyslipidemia but, paradoxically, lower RA disease activity and less cardiovascular disease-related mortality. Rheumatoid cachexia might represent the 'worst of both worlds' with respect to cardiovascular outcome, but until diagnostic criteria for this condition are agreed upon, its effect on cardiovascular disease risk remains controversial.

Entities:  

Mesh:

Year:  2010        PMID: 20647995     DOI: 10.1038/nrrheum.2010.105

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  73 in total

1.  No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis.

Authors:  P Härle; P Sarzi-Puttini; M Cutolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2006-07       Impact factor: 19.103

2.  Nutrient intake patterns, body mass index, and vitamin levels in patients with rheumatoid arthritis.

Authors:  S L Morgan; A M Anderson; S M Hood; P A Matthews; J Y Lee; G S Alarcón
Journal:  Arthritis Care Res       Date:  1997-02

3.  Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis.

Authors:  Inmaculada del Rincón; Gregory L Freeman; Roy W Haas; Daniel H O'Leary; Agustín Escalante
Journal:  Arthritis Rheum       Date:  2005-11

4.  Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis.

Authors:  Samuele M Marcora; Kathryn R Chester; Gayatri Mittal; Andrew B Lemmey; Peter J Maddison
Journal:  Am J Clin Nutr       Date:  2006-12       Impact factor: 7.045

5.  Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor.

Authors:  I-L Engvall; A-C Elkan; B Tengstrand; T Cederholm; K Brismar; I Hafstrom
Journal:  Scand J Rheumatol       Date:  2008 Sep-Oct       Impact factor: 3.641

6.  Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.

Authors:  G S Metsios; A Stavropoulos-Kalinoglou; K M J Douglas; Y Koutedakis; A M Nevill; V F Panoulas; M Kita; G D Kitas
Journal:  Rheumatology (Oxford)       Date:  2007-12       Impact factor: 7.580

Review 7.  Hypertension in rheumatoid arthritis.

Authors:  V F Panoulas; G S Metsios; A V Pace; H John; G J Treharne; M J Banks; G D Kitas
Journal:  Rheumatology (Oxford)       Date:  2008-05-08       Impact factor: 7.580

8.  Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity.

Authors:  Gregorio Navarro-Cano; Inmaculada Del Rincón; Samvel Pogosian; José F Roldán; Agustín Escalante
Journal:  Arthritis Rheum       Date:  2003-09

9.  Cigarette smoking significantly increases basal metabolic rate in patients with rheumatoid arthritis.

Authors:  G S Metsios; A Stavropoulos-Kalinoglou; A M Nevill; K M J Douglas; Y Koutedakis; G D Kitas
Journal:  Ann Rheum Dis       Date:  2008-01       Impact factor: 19.103

10.  Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Ann-Charlotte Elkan; Niclas Håkansson; Johan Frostegård; Tommy Cederholm; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2009-03-10       Impact factor: 5.156

View more
  54 in total

1.  Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis.

Authors:  Rachel A Brown; Domenico Spina; Sayqa Butt; Gregory D Summers
Journal:  Clin Rheumatol       Date:  2011-10-19       Impact factor: 2.980

Review 2.  Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.

Authors:  Eun Ha Kang; Katherine P Liao; Seoyoung C Kim
Journal:  Curr Rheumatol Rep       Date:  2018-05-30       Impact factor: 4.592

Review 3.  Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps.

Authors:  Thomas Zegkos; George Kitas; Theodoros Dimitroulas
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-04-30       Impact factor: 5.346

4.  [Treatment of cardiovascular risk factors].

Authors:  K Krüger
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

5.  Rheumatoid arthritis: Glucocorticoid therapy and body composition.

Authors:  Frank Buttgereit; Gerd R Burmester
Journal:  Nat Rev Rheumatol       Date:  2016-07-07       Impact factor: 20.543

6.  Effect of Megestrol Acetate and Testosterone on Body Composition and Hormonal Responses in COPD Cachexia.

Authors:  Richard Casaburi; Junko Nakata; Lawrence Bistrong; Edwardo Torres; Mehdi Rambod; Janos Porszasz
Journal:  Chronic Obstr Pulm Dis       Date:  2015-11-09

7.  Muscle loss following a single high-dose intramuscular injection of corticosteroids to treat disease flare in patients with rheumatoid arthritis.

Authors:  Andrew B Lemmey; Thomas J Wilkinson; Celine M Perkins; Luke A Nixon; Fazal Sheikh; Jeremy G Jones; Yasmeen A Ahmad; Thomas D O'brien
Journal:  Eur J Rheumatol       Date:  2018-04-02

Review 8.  Rheumatoid arthritis and metabolic syndrome.

Authors:  György Kerekes; Michael T Nurmohamed; Miguel A González-Gay; Ildikó Seres; György Paragh; Zsófia Kardos; Zsuzsa Baráth; László Tamási; Pál Soltész; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2014-08-05       Impact factor: 20.543

Review 9.  Cardiovascular comorbidity in rheumatic diseases.

Authors:  Michael T Nurmohamed; Maaike Heslinga; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2015-08-18       Impact factor: 20.543

Review 10.  Metabolomics--a novel window into inflammatory disease.

Authors:  Martin Fitzpatrick; Stephen P Young
Journal:  Swiss Med Wkly       Date:  2013-01-21       Impact factor: 2.193

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.